Conmed (CNMD) EBITDA (2010 - 2026)

Conmed (CNMD) has reported EBITDA for 17 consecutive years, with $36.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 4.6% year-over-year to $36.4 million; the trailing twelve-month figure through Jun 2026 stood at $110.3 million (down 35.98% YoY), and the FY2025 full-year result was $102.6 million, down 48.77% from the prior year.
• EBITDA improved to $36.4 million in Q2 2026 per CNMD's latest filing, from $25.4 million in the prior quarter.
• Across five years, EBITDA topped out at $65.7 million in Q3 2024 and bottomed at -$1.1 million in Q4 2022.
• Historically, EBITDA has averaged $30.9 million across 5 years, with a median of $28.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: EBITDA sank 102.94% in 2022, then soared 4683.29% in 2023.
• Over 5 years, EBITDA stood at -$1.1 million in 2022, then jumped by 4683.29% to $50.2 million in 2023, then gained by 4.61% to $52.5 million in 2024, then slumped by 30.24% to $36.6 million in 2025, then fell by 0.6% to $36.4 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $36.4 million, $25.4 million, and $36.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.